A pure-play airway clearance compounder: elite margins, rising sales-force productivity, and a huge underdiagnosed bronchiectasis runway—tempered by reimbursement and big-cap competitive risk.
Overview
Electromed (ELMD) is a focused med-tech company centered on a single product platform—the SmartVest Airway Clearance System—serving patients who need High-Frequency Chest Wall Oscillation therapy due to bronchiectasis (non-CF and CF) and neuromuscular disorders. The company differentiates itself with a vertically integrated, direct-to-patient commercial model that combines a specialized homecare sales force, an internal reimbursement team to secure Medicare/Medicaid/commercial approvals, direct shipment, and in-home clinical training. The U.S. accounts for ~99.6% of revenue, with Homecare representing 90%+ of sales (Q2 FY26), complemented by Hospital sales (acute-care secretion management) and a Homecare Distributor/DME partner channel. The opportunity is large and underpenetrated: ~923k diagnosed bronchiectasis patients in the U.S. with only ~16% using HFCWO, plus potential for ~4M undiagnosed cases as imaging (HRCT) and awareness improve. Financially, ELMD appears to be at an inflection point with 13 straight quarters of YoY revenue and profit growth (as of 12/31/2025), sustained gross margin above ~78%, strong ROIC (~27%), and a debt-free balance sheet with ~$13.8M cash—enabling continued sales expansion, product investment, and shareholder returns via buybacks.